Prevalence and incidence of cancer related lymphedema in low and middle-income countries: a systematic review and meta-analysis.
Antineoplastic Agents
/ adverse effects
Arm
Breast Neoplasms
/ complications
Chemoradiotherapy, Adjuvant
/ adverse effects
Cross-Sectional Studies
Developing Countries
/ statistics & numerical data
Female
Genital Neoplasms, Female
/ complications
Humans
Hysterectomy
/ adverse effects
Incidence
Lymph Node Excision
/ adverse effects
Lymphedema
/ epidemiology
Mastectomy
/ adverse effects
Prevalence
Quality of Life
Risk Factors
Cancer related lymphedema
Incidence
LMICs
Lymphedema
Prevalence
Risk factor
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
29 Jun 2020
29 Jun 2020
Historique:
received:
31
03
2020
accepted:
15
06
2020
entrez:
1
7
2020
pubmed:
1
7
2020
medline:
30
1
2021
Statut:
epublish
Résumé
Little is known about the prevalence and incidence in low and middle-income countries (LMICs) of secondary lymphedema due to cancer. The purpose of the study is to estimate the prevalence and incidence in LMICs of secondary lymphedema related to cancer and/or its treatment(s) and identify risk factors. A systematic review and meta-analysis was conducted. Medline, EMBASE and CINAHL were searched in June 2019 for peer-reviewed articles that assessed prevalence and/or incidence of cancer-related lymphedema in LMICs. Risk of bias was assessed using the Joanna Briggs Institute Critical Appraisal Checklist for Prevalence Studies. Estimates of pooled prevalence and incidence estimates were calculated with 95% confidence intervals (CI), with sub-group analyses grouping studies according to: country of origin, study design, risk of bias, setting, treatment, and lymphedema site and measurement. Heterogeneity was measured using X Of 8766 articles, 36 were included. Most reported on arm lymphedema secondary to breast cancer treatment (n = 31), with the remainder reporting on leg lymphedema following gynecological cancer treatment (n = 5). Arm lymphedema was mostly measured by arm circumference (n = 16/31 studies), and leg lymphedema through self-report (n = 3/5 studies). Eight studies used more than one lymphedema measurement. Only two studies that measured prevalence of leg lymphedema could be included in a meta-analysis (pooled prevalence =10.0, 95% CI 7.0-13.0, I Better understanding the factors that contribute to variability in cancer-related arm lymphedema in LMICs is an important first step to developing targeted interventions to improve quality of life. Standardising measurement of lymphedema globally and better reporting would enable comparison within the context of information about cancer treatments and lymphedema care.
Sections du résumé
BACKGROUND
BACKGROUND
Little is known about the prevalence and incidence in low and middle-income countries (LMICs) of secondary lymphedema due to cancer. The purpose of the study is to estimate the prevalence and incidence in LMICs of secondary lymphedema related to cancer and/or its treatment(s) and identify risk factors.
METHOD
METHODS
A systematic review and meta-analysis was conducted. Medline, EMBASE and CINAHL were searched in June 2019 for peer-reviewed articles that assessed prevalence and/or incidence of cancer-related lymphedema in LMICs. Risk of bias was assessed using the Joanna Briggs Institute Critical Appraisal Checklist for Prevalence Studies. Estimates of pooled prevalence and incidence estimates were calculated with 95% confidence intervals (CI), with sub-group analyses grouping studies according to: country of origin, study design, risk of bias, setting, treatment, and lymphedema site and measurement. Heterogeneity was measured using X
RESULTS
RESULTS
Of 8766 articles, 36 were included. Most reported on arm lymphedema secondary to breast cancer treatment (n = 31), with the remainder reporting on leg lymphedema following gynecological cancer treatment (n = 5). Arm lymphedema was mostly measured by arm circumference (n = 16/31 studies), and leg lymphedema through self-report (n = 3/5 studies). Eight studies used more than one lymphedema measurement. Only two studies that measured prevalence of leg lymphedema could be included in a meta-analysis (pooled prevalence =10.0, 95% CI 7.0-13.0, I
CONCLUSION
CONCLUSIONS
Better understanding the factors that contribute to variability in cancer-related arm lymphedema in LMICs is an important first step to developing targeted interventions to improve quality of life. Standardising measurement of lymphedema globally and better reporting would enable comparison within the context of information about cancer treatments and lymphedema care.
Identifiants
pubmed: 32600278
doi: 10.1186/s12885-020-07079-7
pii: 10.1186/s12885-020-07079-7
pmc: PMC7325022
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
604Références
Eur J Cancer Care (Engl). 2008 Nov;17(6):557-64
pubmed: 18771539
Asian Pac J Cancer Prev. 2016;17(S3):81-6
pubmed: 27165213
Cancer. 2012 Apr 15;118(8 Suppl):2237-49
pubmed: 22488698
Saudi Med J. 2013 Jan;34(1):62-6
pubmed: 23299161
ANZ J Surg. 2001 Oct;71(10):590-3
pubmed: 11552933
Cancer Nurs. 2008 Jul-Aug;31(4):302-9; quiz 310-1
pubmed: 18600117
World J Surg Oncol. 2010 Nov 01;8:94
pubmed: 21040577
Eur J Obstet Gynecol Reprod Biol. 2012 Nov;165(1):91-5
pubmed: 22795579
Breast. 2012 Jun;21(3):361-5
pubmed: 22460058
Asian Pac J Cancer Prev. 2014;15(6):2505-10
pubmed: 24761855
Ann Oncol. 2007 Apr;18(4):639-46
pubmed: 17018707
Support Care Cancer. 2019 Feb;27(2):495-503
pubmed: 29980907
Cancer. 2012 Apr 15;118(8 Suppl):2325-30
pubmed: 22488706
Lancet Oncol. 2013 May;14(6):500-15
pubmed: 23540561
J Clin Oncol. 2012 Oct 20;30(30):3726-33
pubmed: 23008299
Int J Health Policy Manag. 2014 Aug 13;3(3):123-8
pubmed: 25197676
Turk J Phys Med Rehabil. 2018 Jul 09;64(3):205-212
pubmed: 31453513
Am J Surg. 2004 Jan;187(1):69-72
pubmed: 14706589
PLoS Med. 2009 Jul 21;6(7):e1000100
pubmed: 19621070
Eur J Cancer Care (Engl). 2017 Jul;26(4):
pubmed: 26764197
Indian J Cancer. 2004 Jan-Mar;41(1):8-12
pubmed: 15105573
Acupunct Med. 2008 Jun;26(2):87-93
pubmed: 18591908
Lymphat Res Biol. 2011;9(2):101-7
pubmed: 21688979
Ann Surg Oncol. 2009 Jul;16(7):1959-72
pubmed: 19365624
J Med Life. 2014 Mar 15;7(1):60-6
pubmed: 24653760
S Afr J Surg. 2014 Jun 06;52(2):41-4
pubmed: 25216094
BMC Womens Health. 2013 Feb 13;13:6
pubmed: 23406386
J Clin Med. 2019 Jan 24;8(2):
pubmed: 30682851
Semin Plast Surg. 2018 Feb;32(1):17-21
pubmed: 29636649
Chirurgia (Bucur). 2015 Jan-Feb;110(1):33-7
pubmed: 25800313
J Am Acad Dermatol. 2017 Dec;77(6):1009-1020
pubmed: 29132848
Rev Assoc Med Bras (1992). 2018 Jul;64(7):627-634
pubmed: 30365665
Int J Breast Cancer. 2012;2012:689168
pubmed: 22295249
BMC Cancer. 2020 Jun 29;20(1):604
pubmed: 32600278
Asian Pac J Cancer Prev. 2011;12(11):2939-42
pubmed: 22393967
Breast Cancer. 2010 Oct;17(4):281-5
pubmed: 19789952
J Palliat Care. 2013 Winter;29(4):253-7
pubmed: 24601078
Breast. 2013 Oct;22(5):606-15
pubmed: 24007941
Dakar Med. 2001;46(1):39-42
pubmed: 15773155
Rev Bras Fisioter. 2011 Mar-Apr;15(2):146-53
pubmed: 21789365
Biomed Res Int. 2013;2013:807569
pubmed: 23853774
Breast Cancer Res Treat. 2011 Feb;125(3):893-902
pubmed: 20853176
Br J Community Nurs. 2016 Apr;Suppl:S6-14
pubmed: 27046432
Indian J Cancer. 2018 Apr-Jun;55(2):184-189
pubmed: 30604734
Int J Evid Based Healthc. 2015 Sep;13(3):147-53
pubmed: 26317388
Arch Phys Med Rehabil. 2015 Jun;96(6):1131-9
pubmed: 25637862
J Cancer Educ. 2017 Sep;32(3):629-633
pubmed: 27048148
Dtsch Arztebl Int. 2010 Mar;107(11):187-92
pubmed: 20386677
Lymphat Res Biol. 2015 Mar;13(1):40-5
pubmed: 25526543
Cancer Invest. 2010 Jan;28(1):54-62
pubmed: 19916749